digital currency payment- Top Featured snippets

The RMB exchange rate is expected to appreciate again at the end of the year. The research team of the Financial Market Department of Agricultural Bank of China said that the market transactions have shown obvious narrative-driven characteristics in recent years. Considering some recent changes, the RMB exchange rate is expected to stabilize and rebound again in the future. First, the pricing of Trump transactions in the international market has come to an end. Second, there has been a major shift in domestic macro policies. Since late September, financial policies such as lowering the RRR, cutting interest rates, supporting the stock market and the real estate market, and fiscal debt measures have boosted market confidence. Third, there has been a favorable change in supply and demand in the domestic foreign exchange market. The end of the year is the traditional peak season for enterprises to settle foreign exchange, and the continuous forward discount will lead to the backlog of foreign exchange settlement, which will further amplify the demand for foreign exchange settlement at the end of the year. Further considering the overall situation of the game between China and the United States, Trump's return not only means the enhancement of external shocks, but also the upgrading of internal policies. The RMB exchange rate will maintain two-way fluctuations next year, and it is no longer a steady profit for enterprises to hold US dollars and postpone foreign exchange settlement. While stabilizing domestic foreign trade and foreign investment, continuing to expand high-level opening-up and expanding domestic demand in an all-round way implies the certainty of economic stabilization and recovery, which is expected to promote the return of short-term securities investment and medium-and long-term direct investment and help the RMB stop falling and rebound.Schlegel, Governor of the Swiss National Bank: We still have ammunition left over in terms of interest rates. Inflationary pressure has dropped in the medium term. Our main tool is the policy interest rate, through which we can influence the economy and exchange rate.South Korea's National Assembly passed "Yin Xiyue's General Special Inspection Law" and "Jin Jianxit's Inspection Law". The reporter of the General Station was informed that on the 12th local time, South Korea's National Assembly held a general meeting of parliamentarians and passed "Yin Xiyue's General Special Inspection Law" and "Jin Jianxit's Inspection Law". (CCTV News)

Botuo Bio: Adjust the profit distribution plan for the first three quarters of 2024. Botuo Bio announced that the total amount of cash dividends to be distributed in the company's profit distribution for the first three quarters of 2024 was adjusted from RMB 52.2583 million to RMB 53.2083 million. Before the adjustment, the company's total share capital was 105 million shares after deducting the shares in the company's repurchase special securities account, and a total cash dividend of 52.2583 million yuan was planned to be distributed. After adjustment, the company's total share capital is 107 million shares, of which 250,000 shares are repurchased in the special securities account, and the total number of shares actually participating in the profit distribution of the company is 106 million shares, with a total cash dividend of 53,208,300 yuan.Schlegel, Governor of Swiss National Bank: If monetary policy needs to be further relaxed, interest rate reduction is still the main tool. The Swiss National Bank is still willing to intervene in the foreign exchange market when necessary.Dongpeng Beverage has set up two new companies in Hainan. According to the enterprise search APP, Hainan Dongpeng Beverage Marketing Co., Ltd. and Hainan Dongpeng Food & Beverage Co., Ltd. were established recently, and their legal representatives are both Liu Meili, with a registered capital of 100 million yuan. Enterprise investigation shows that both of them are wholly owned by Dongpeng Beverage.

Schlegel, Governor of Swiss National Bank: If monetary policy needs to be further relaxed, interest rate reduction is still the main tool. The Swiss National Bank is still willing to intervene in the foreign exchange market when necessary.Interbank certificates of deposit funds are popular. In the context of the current downward trend of non-bank interbank deposit rates, interbank deposit rates are relatively more attractive, and interbank deposit funds have recently gained popularity. Since December, the 7-day holding fund of AAA index of China Securities Interbank Deposits issued by BlackRock Fund and Agricultural Bank of China Credit Suisse Fund has reached the upper limit of 5 billion yuan, and triggered proportional placement. Both funds are partially confirmed by the principle of "doomsday ratio confirmation", and the doomsday confirmation ratio is 73.36% and 27.02% respectively. In addition, Huatai Bairui Fund and China-Canada Fund also imposed subscription restrictions on their 7-day holding funds of the AAA Index of China Securities Interbank Deposits. From December 11th, the amount of multiple cumulative subscriptions (including conversion and fixed investment) for a single fund account of Huatai Bairui CSI Interbank Deposit Certificate AAA Index 7-day holding fund shall not exceed 100,000 yuan; From December 6th, the subscription amount of a single investor of the 7-day holding fund of China-Canada CSI Interbank Deposit Certificate AAA Index will not exceed 10 million yuan (except for individual investors and public asset management products). (CSI Taurus)Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.